Patents Examined by Matthew P Coughlin
-
Patent number: 12129246Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.Type: GrantFiled: February 28, 2024Date of Patent: October 29, 2024Assignee: Novartis AGInventors: Daniela Angst, Philippe Bolduc, Matthew William Carson, Atwood Kim Cheung, Véronique Darsigny, Xiang Gao, Viktor Hornak, Keith Jendza, Rajesh Karki, Ajay Kumar Lal, Gang Liu, Justin Yik Ching Mao, Jeffrey M. McKenna, Erik Meredith, Muneto Mogi, Vivek Rauniyar, Liansheng Su, Ritesh Tichkule, Shuangxi Wang, Chun Zhang, Liang Zhao, Rui Zheng
-
Patent number: 12122759Abstract: The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.Type: GrantFiled: November 6, 2018Date of Patent: October 22, 2024Assignees: ELANCO ANIMAL HEALTH GMBH, THE KITASATO INSTITUTEInventors: Dirk Heimbach, Satoshi Omura, Toshiaki Sunazuka, Tomoyasu Hirose, Yoshihiko Noguchi, Johannes Köbberling, Zhijie Wu, Shuibiao Fu, Wei Wu, Jinfeng Qiu, Liu He, Xudong Wei
-
Patent number: 12122776Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.Type: GrantFiled: May 12, 2023Date of Patent: October 22, 2024Assignee: Gilead Sciences, Inc.Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
-
Patent number: 12122758Abstract: The invention provides a material comprising (i) a crown ether of formula (I) and/or (ii) a crown ether of formula (II), or a salt thereof, wherein each m independently is an integer from 1 to 8, each “” designates an optionally present bond and/or structure, each X independently is —N(R1)2, —N*(R1), —N**, —N*(R1)2+Z?, or —N**(R1)+Z?, provided at least one X is —N*(R1), —N**, —N*(R1)2+Z?, or —N**(R1)+Z?, wherein each R1 independently is hydrogen or C1-6 alkyl, each Z is optionally present and independently is a counterion to balance the charge on nitrogen, and * represents a bond to a remainder of the material, a method of making the material, and a method of using the material.Type: GrantFiled: September 5, 2023Date of Patent: October 22, 2024Assignee: Pall CorporationInventors: Andrew Kocen, Rehanah Sejoubsari, Ahmad Arabi Shams Abadi
-
Patent number: 12116349Abstract: The invention provides a novel compound having the general formula (I) or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.Type: GrantFiled: June 8, 2022Date of Patent: October 15, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Francesco Tommaso Pettazzoni, Juergen Wichmann
-
Patent number: 12110292Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.Type: GrantFiled: November 11, 2022Date of Patent: October 8, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Patent number: 12110280Abstract: A method for synthesizing cyclic carbonate monomers using carbon dioxide (CO2) is provided. The method also includes combining reagents to synthesize the cyclic carbonate monomer, the reagents including a substrate that is a 1,X-diol, where X is between 2 and 5, a base that is a tertiary amine, a promoter that is a multidentate, bis-tertiary amine base where nitrogens are separated by 2 to 4 carbon atoms, a solvent, and CO2.Type: GrantFiled: June 17, 2021Date of Patent: October 8, 2024Assignee: International Business Machines CorporationInventors: Nathaniel H. Park, Victoria A Piunova, Dmitry Zubarev, Tim Erdmann, Pedro Arrechea, James L. Hedrick
-
Patent number: 12102608Abstract: A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages): oleoylethanolamide (OEA) C18:1 60-65%? palmitoylethanolamide (PEA) C16:0 5-20% linoleylethanolamide (LEA) C18:2 5-20% stearoylethanolamide (SEA) C18:0 ?1-2% palmitoylethanolamide (POEA) C16:1 0.1-0.8%? myristoylethanolamide (MEA) C14:0 0.02-0.15%?? mixture of glycerides ?4-6% glycerol ?6-8%. A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.Type: GrantFiled: May 26, 2022Date of Patent: October 1, 2024Assignee: EPITECH GROUP S.P.A.Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Chiara Gomiero
-
Patent number: 12102712Abstract: A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone, fluocinonide, or clobetasol. The antifungal and steroid may be within a cream. In one example, a commercially available econazole nitrate cream may be used in conjunction with a commercially available fluocinonide cream or commercially available clobetasol cream to treat the affected skin area.Type: GrantFiled: May 3, 2021Date of Patent: October 1, 2024Assignee: CMPD Licensing LLCInventor: Jay Richard Ray
-
Patent number: 12103904Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.Type: GrantFiled: March 19, 2021Date of Patent: October 1, 2024Assignees: Duke University, The University of North Carolina at Chapel HillInventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
-
Patent number: 12103914Abstract: The present application discloses, in part, isolated, stable and biologically active menaquinol derivatives and their methods of use for the treatment of various diseases.Type: GrantFiled: December 28, 2021Date of Patent: October 1, 2024Assignee: Epizon Pharma, Inc.Inventors: John M. Rudey, Eric Stephen Gruff, Sam L. Nguyen
-
Patent number: 12098129Abstract: To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II): wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12, or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.Type: GrantFiled: September 26, 2019Date of Patent: September 24, 2024Assignees: LTT BIO-PHARMA CO., LTD., MUSASHINO UNIVERSITYInventors: Tohru Mizushima, Ken-ichiro Tanaka
-
Patent number: 12098115Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: July 31, 2023Date of Patent: September 24, 2024Assignee: University of Florida Research Foundation, INC.Inventor: Alexander James Grenning
-
Patent number: 12098141Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.Type: GrantFiled: December 20, 2022Date of Patent: September 24, 2024Assignee: Corcept Therapeutics IncorporatedInventors: Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
-
Patent number: 12098116Abstract: Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.Type: GrantFiled: February 14, 2023Date of Patent: September 24, 2024Assignee: UNITED THERAPEUTICS CORPORATIONInventor: Kenneth Phares
-
Patent number: 12091431Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.Type: GrantFiled: July 12, 2023Date of Patent: September 17, 2024Assignee: Aeromics, Inc.Inventors: Paul Robert Mcguirk, Robert Zamboni, Melanie Bevill, Stephan Parent
-
Patent number: 12091410Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: December 11, 2019Date of Patent: September 17, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Yoshito Terao, Masanori Kawasaki
-
Patent number: 12091411Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: January 31, 2023Date of Patent: September 17, 2024Assignee: Kymera Therapeutics, Inc.Inventors: Nello Mainolfi, Chris De Savi, Matthew M. Weiss, Xiao Zhu, Xiaozhang Zheng, Bruce C. Follows
-
Patent number: 12091398Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.Type: GrantFiled: February 20, 2020Date of Patent: September 17, 2024Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Pan Li, Beidi Xu, Qiaodong Wen, Enguang Feng, Ji Wang, Yang Lu, Yu Zhou, Zhiyong Yu, Zhiying Huang
-
Patent number: 12084579Abstract: Disclosed herein are receptor-substrate complexes comprising an octacationic tricyclic cyclophane and a pyrrole dye complexed therein and methods of using and making the same.Type: GrantFiled: August 13, 2021Date of Patent: September 10, 2024Assignee: Northwestern UniversityInventors: James Fraser Stoddart, Wenqi Liu